BRPI0507585A - agonistas seletivos do receptor y2 para intervenções terapêuticas - Google Patents

agonistas seletivos do receptor y2 para intervenções terapêuticas

Info

Publication number
BRPI0507585A
BRPI0507585A BRPI0507585-8A BRPI0507585A BRPI0507585A BR PI0507585 A BRPI0507585 A BR PI0507585A BR PI0507585 A BRPI0507585 A BR PI0507585A BR PI0507585 A BRPI0507585 A BR PI0507585A
Authority
BR
Brazil
Prior art keywords
receptor
amino acid
terminal
npy
agonist
Prior art date
Application number
BRPI0507585-8A
Other languages
English (en)
Inventor
Thue Schwartz
Original Assignee
7Tm Pharmas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500586A external-priority patent/GB0500586D0/en
Application filed by 7Tm Pharmas As filed Critical 7Tm Pharmas As
Publication of BRPI0507585A publication Critical patent/BRPI0507585A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

AGONISTAS SELETIVOS DO RECEPTOR Y2 PARA INTERVENçõES TERAPêUTICAS. A presente invenção refere-se a agonistas de receptores Y diferentes de PYY3-36, que são seletivos para o receptor Y2 em detrimento dos receptores Y2 e Y4, e seu uso no tratamento de condições responsivas à ativação de receptores Y2. Genericamente, um agonista seletivo de Y2 é um que (a) é um peptídeo com dobra de PP ou mimético de peptídeo com dobra de PP selecionado entre os miméticos PYY, NPY e PYY, e miméticos NPY que têm uma seqüência de aminoácidos de reconhecimento do receptor Y2 no terminal C, e têm várias modificações em relação aos peptídeos naturais, ou (b) é um peptídeo com dobra de PP ou mimético de peptídeo com dobra de PP selecionado entre PP e miméticos de PP que têm uma seqüência de aminoácidos de reconhecimento do receptor Y2 no terminal C, e têm várias modificações em relação aos peptídeos naturais, ou (c) compreende (i) uma seqüência de aminoácidos de reconhecimento do receptor Y2 no terminal C, fundida em seu terminal N a um domínio de seqüência de aminoácidos anfifílico, compreendendo pelo menos uma volta helicoidal alfa adjacente ao terminal N da dita seqüência de reconhecimento do receptor Y2, sendo a dita volta restringida em uma configuração helicoidal por uma ligação intra-molecular covalente, e (ii) no caso em que o agonista tem uma estrutura do terminal N análoga a NPY ou PPY, tendo uma ou mais das modificações listadas em (a) acima, e, no caso em que o agonista tem uma estrutura do terminal N análoga a PP, tendo uma ou mais das modificações listadas em (b) acima.
BRPI0507585-8A 2004-03-17 2005-03-17 agonistas seletivos do receptor y2 para intervenções terapêuticas BRPI0507585A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200400436 2004-03-17
US55893204P 2004-04-01 2004-04-01
US58596404P 2004-07-06 2004-07-06
GB0500586A GB0500586D0 (en) 2005-01-12 2005-01-12 Y2 selective receptor agonists for therapeutic interventions
PCT/EP2005/002981 WO2005089789A2 (en) 2004-03-17 2005-03-17 Y2 selective receptor agonists for therapeutic interventions

Publications (1)

Publication Number Publication Date
BRPI0507585A true BRPI0507585A (pt) 2007-07-03

Family

ID=34963771

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507585-8A BRPI0507585A (pt) 2004-03-17 2005-03-17 agonistas seletivos do receptor y2 para intervenções terapêuticas

Country Status (9)

Country Link
EP (2) EP1807099A2 (pt)
JP (1) JP2007531713A (pt)
AU (1) AU2005224026A1 (pt)
BR (1) BRPI0507585A (pt)
CA (1) CA2559838A1 (pt)
EA (1) EA011860B1 (pt)
IL (1) IL177683A0 (pt)
MX (1) MXPA06010347A (pt)
WO (1) WO2005089789A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0520563A2 (pt) 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y4 seletivos para intervenções terapêuticas
WO2007038943A1 (en) * 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
JP2010533157A (ja) * 2007-07-09 2010-10-21 インペリアル イノベーションズ リミテッド ヒト膵臓ポリペプチド（ｈｐｐ）類似体および摂食行動に対するそれらの影響
KR20100057048A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 펩티드 ｈｉｓ－ｓｅｒ－ｌｅｕ－ｇｌｙ－ｌｙｓ－ｔｒｐ－ｌｅｕ－ｇｌｙ－ｈｉｓ－ｐｒｏ－ａｓｐ－ｌｙｓ－ｐｈｅ 단독 또는 펩티드 ｇｌｙ－ａｒｇ－ｇｌｙ－ａｓｐ－ａｓｎ－ｐｒｏ－ｏｈ와의 배합물의 치료제로서의 용도
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
HUE036066T2 (hu) 2010-12-16 2018-06-28 Novo Nordisk As GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
RU2641198C3 (ru) 2012-03-22 2021-12-10 Ново Нордиск А/С Композиции glp-1 пептидов и их получение
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
MY187047A (en) 2015-06-12 2021-08-27 Novo Nordisk As Selective pyy compounds and uses thereof
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
GB201720188D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
PE20210453A1 (es) 2018-02-02 2021-03-08 Novo Nordisk As Composiciones solidas que comprenden un agonista de glp-1, una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202014433A (zh) * 2018-04-25 2020-04-16 比利時商健生藥品公司 類升糖素肽１（ｇｌｐ－１）融合肽偶合環狀酪酪肽接合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JPH08510205A (ja) * 1993-03-29 1996-10-29 ユニバーシティ オブ シンシナティ Ｙｙペプチドのアナログとその用途
PL183698B1 (pl) 1995-03-17 2002-06-28 Novo Nordisk As Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
JP2004515533A (ja) * 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝障害を治療するためのペプチドｙｙおよびペプチドｙｙアゴニスト
DE60335639D1 (de) 2002-06-14 2011-02-17 Amylin Pharmaceuticals Inc Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
WO2005053726A1 (en) * 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
AU2005211776B2 (en) * 2004-02-11 2012-02-02 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same

Also Published As

Publication number Publication date
EP1807099A2 (en) 2007-07-18
EP2272524A2 (en) 2011-01-12
EA011860B1 (ru) 2009-06-30
CA2559838A1 (en) 2005-09-29
AU2005224026A1 (en) 2005-09-29
WO2005089789A3 (en) 2006-02-09
MXPA06010347A (es) 2007-06-19
WO2005089789A2 (en) 2005-09-29
IL177683A0 (en) 2006-12-31
EA200601721A1 (ru) 2007-04-27
EP2272524A3 (en) 2011-02-02
JP2007531713A (ja) 2007-11-08

Similar Documents

Publication Publication Date Title
BRPI0507585A (pt) agonistas seletivos do receptor y2 para intervenções terapêuticas
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
PE20220283A1 (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
HRP20201353T1 (hr) Agonisti glukagonskog receptora
BR0213132A (pt) Açao de peptìdeos tanto como agonistas receptores de glp1 quanto antagonistas receptores de glucagon e seus métodos farmacológicos de uso
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
BR112013013548B8 (pt) Proteína de fusão anticancerígena
PH12019501656A1 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
PE20061412A1 (es) Agonistas de peptidos pyy pegilados
Joshi et al. Endogenous PYY and GLP‐1 mediate l‐glutamine responses in intestinal mucosa
EA200900667A1 (ru) Селективные аналоги глюкагонподобного пептида-2 (glp-2)
AR069157A1 (es) Antagonista especifico para el factor 8 de crecimiento y diferenciacion (gdf8), polinucleotido que codifica los aminoacidos que comprenden el antagonista gdf8 , celula anfitriona y vector que comprenden el polinucleotido, celula anfitriona que comprende el vector, metodo para producir un antagonista
BRPI0508861A (pt) agonistas do receptor y2/y4 seletivo para intervenções terapêuticas
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
AR096162A1 (es) Péptidos terapéuticos
EA200600055A1 (ru) Агонисты рецептора меланокортина 4 (мк4 ) и их применение
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
AR075998A1 (es) Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
KR20210024081A (ko) 당뇨병을 위한 gip/glp1 공효능제의 사용 방법
Stangl et al. Photoaffinity labeling of rat calcitonin gene-related peptide receptors and adenylate cyclase activation: identification of receptor subtypes
Fichna et al. Opioid peptides in cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.